Ernexa Therapeutics (ERNA) vs HCW Biologics (HCWB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Ernexa Therapeutics is the larger company by market cap ($4.1 million vs $3.4 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ERNA | HCWB |
|---|---|---|
| Share price | $2.49 | $1.53 |
| Market cap | $4.06M | $3.42M |
| 1-day change | +4.18% | -1.92% |
| EPS (TTM) | $-14.73 | $-19.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $71.50 | $27.57 |
| 52-week low | $2.14 | $1.50 |
| Distance from 52-week high | -96.52% | -94.45% |
| Analyst consensus | none | buy |
| Avg. price target upside | +1104.82% | +3037.25% |
| Average volume | 472.81K | 376.23K |
| Shares outstanding | 1.63M | 2.24M |
| Employees | 5 | 35 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Ernexa Therapeutics
ERNA stock →Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis.
Healthcare · Biotechnology · 5 employees
About HCW Biologics
HCWB stock →HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases.
Healthcare · Biotechnology · 35 employees
ERNA vs HCWB FAQ
Which is bigger, Ernexa Therapeutics or HCW Biologics?
Ernexa Therapeutics (ERNA) is larger, with a market capitalization of $4.06M compared with $3.42M for HCW Biologics (HCWB).
Are Ernexa Therapeutics and HCW Biologics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.